1. Helfand BK, Webb M, Gartaganis SL, Fuller L, Kwon CS, Inouye SK. The exclusion of older persons from vaccine and treatment trials for coronavirus disease 2019: missing the target. JAMA Intern Med 2020;180:1546–1549.

2. Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting. N Engl J Med 2021;385:1078–1090.

3. Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation 2021;144:471–484.

4. Huynh A, Kelton JG, Arnold DM, Daka M, Nazy I. Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia. Nature 2021;596:565–569.

5. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021;384:2092–2101.

6. Klok FA, Pai M, Huisman MV, Makris M. Vaccine-induced immune thrombotic thrombocytopenia. Lancet Haematol 2022;9:e73–e80.

7. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020;383:2603–2615.

8. Voysey M, Clemens SA, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV- 2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99–111.

9. Miller E. Rapid evaluation of the safety of COVID-19 vaccines: how well have we done? Clin Microbiol Infect 2022;28:477–478.

10. Watanabe S, Waseda Y, Takato H, et al. Influenza vaccine-induced interstitial lung disease. Eur Respir J 2013;41:474–477.

11. Niebel D, Novak N, Wilhelmi J, et al. Cutaneous adverse reactions to COVID-19 vaccines: insights from an immuno-dermatological perspective. Vaccines (Basel) 2021;9:944.

12. Johkoh T, Lee KS, Nishino M, et al. Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner Society. Chest 2021;159:1107–1125.

13. Park JY, Kim JH, Lee IJ, et al. COVID-19 vaccine-related interstitial lung disease: a case study. Thorax 2022;77:102–104.

14. Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration 2004;71:301–326.

15. Korea Disease Control and Prevention Agency. Weekly analysis of adverse reactions after COVID-19 vaccination [Internet] Cheongju (KR): Korea Disease Control and Prevention Agency, 2022. [cited 2022 Jul 11]. Available from: https://ncv.kdca.go.kr/board.es?mid=a11707010000&bid=0032 . 17. Park JY, Kim HI, Kim JH, et al. Changes in respiratory virus infection trends during the COVID-19 pandemic in South Korea: the effectiveness of public health measures. Korean J Intern Med 2021;36:1157–1168.

18. Huh K, Kim YE, Ji W, et al. Decrease in hospital admissions for respiratory diseases during the COVID-19 pandemic: a nationwide claims study. Thorax 2021;76:939–941.

19. Cagigi A, Lore K. Immune responses induced by mRNA vaccination in mice, monkeys and humans. Vaccines (Basel) 2021;9:61.

20. Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front Immunol 2021;11:617089.

21. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum 1997;40:1601–1611.

22. Rijkers GT, Weterings N, Obregon-Henao A, et al. Antigen presentation of mRNA-based and virus-vectored SARS-CoV-2 vaccines. Vaccines (Basel) 2021;9:848.

23. Chan AT, Tang SC. De novo and relapsing glomerulonephritis after COVID-19 vaccination: how much do we know? Nephrology (Carlton) 2022;27:5–6.

24. Skeoch S, Weatherley N, Swift AJ, et al. Drug-induced interstitial lung disease: a systematic review. J Clin Med 2018;7:356.

25. Shimizu T, Watanabe S, Yoneda T, et al. Interstitial pneumonitis after COVID-19 vaccination: a report of three cases. Allergol Int 2022;71:251–253.

26. Kono A, Yoshioka R, Hawk P, et al. A case of severe interstitial lung disease after COVID-19 vaccination. QJM 2022;114:805–806.

27. Matsuzaki S, Kamiya H, Inoshima I, Hirasawa Y, Tago O, Arai M. COVID-19 mRNA vaccine-induced pneumonitis. Intern Med 2022;61:81–86.

28. Yoshifuji A, Ishioka K, Masuzawa Y, et al. COVID-19 vaccine induced interstitial lung disease. J Infect Chemother 2022;28:95–98.

29. Piqueras MB, Casajus AE, Rodero CF, et al. Acute eosinophilic pneumonia following mRNA COVID-19 vaccination: a case report. Arch Bronconeumol 2022;58(Suppl 1):53–54.

30. Stoyanov A, Thompson G, Lee M, Katelaris C. Delayed hypersensitivity to the Comirnaty coronavirus disease 2019 vaccine presenting with pneumonitis and rash. Ann Allergy Asthma Immunol 2022;128:321–322.

31. Amiya S, Fujimoto J, Matsumoto K, et al. Case report: acute exacerbation of interstitial pneumonia related to messenger RNA COVID-19 vaccination. Int J Infect Dis 2022;116:255–257.

32. Wang T, Cayetano KS, Parvataneni CK, Paranada K, Sanchez-Metz C, Haws CR. Combined myopericarditis and pneumonitis post–Pfizer vaccine against coronavirus disease 2019 in a healthy Caucasian middle-aged man. Infect Dis Clin Pract 2022;30:e1097.

33. Miqdadi A, Herrag M. Acute eosinophilic pneumonia associated with the anti-COVID-19 vaccine AZD1222. Cureus 2021;13:e18959.

34. Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis: an International Working Group Report. Am J Respir Crit Care Med 2016;194:265–275.